Last reviewed · How we verify
NCT02849977
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
trial in Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations in 5,966 participants. Completed in 9 June 2020.
9 June 2020
Quick facts
| Lead sponsor | Rhythm Pharmaceuticals, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,966 |
| Start date | 28 September 2016 |
| Primary completion | 9 June 2020 |
| Estimated completion | 9 June 2020 |
| Sites | 58 locations across Italy, Greece, Israel, Germany, Canada, Portugal, United States |
Conditions studied
- Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations — all drugs for Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations →
Sponsor
Rhythm Pharmaceuticals, Inc. — full company profile →
Who can join
2 and older, any sex, with Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this screening study is to identify people who have a rare genetic cause of obesity - specifically three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that are currently known to result in obesity. This screening study will not include any investigational drugs. You will be asked to provide a DNA sample and answer some questions about your medical history and hunger.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02849977
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Rhythm Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07156578 — A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) · Phase 2 · enrolling by invitation
- NCT06760546 — A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) · Phase 3 · recruiting
- NCT06772597 — A Study of Setmelanotide in Patients With Prader-Willi Syndrome · Phase 2 · active not recruiting
- NCT06596135 — Open-Label Extension Study of Setmelanotide · Phase 3 · enrolling by invitation
- NCT06046443 — A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02849977 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rhythm Pharmaceuticals, Inc.
- Last refreshed: 15 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02849977.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing